Education
About Us
Working with TipRanks
Follow Us
Cogstate Ltd (COGZF)
OTHER OTC:COGZF
Earnings Data
Report Date
Feb 25, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
―Last Year’s EPS
0.02Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
Cogstate reported strong financial performance with significant revenue and profit growth. The company is expanding its market reach and capabilities through strategic partnerships and product innovations, particularly with its partnership with Medidata and the development of AI-powered products. However, there are challenges such as a decline in healthcare revenue and potential margin pressure due to increased investments.Company Guidance
Strong Financial Performance
Cogstate reported a total revenue of $53.1 million for the year, up 22% from the previous year. Clinical Trials revenue increased by 28% to $50.6 million. Profit before tax rose by 96% to $13.9 million, and profit after tax increased by 86% to $10.1 million.
High Margins and Cash Flow
The company achieved a gross margin of 61%, an EBITDA margin of 30%, and an EBIT margin of 25%. Operating cash inflow was $11.5 million, and the cash balance at the end of the financial year was $35.6 million.
Maiden Dividend Announcement
Cogstate declared its first fully franked dividend of AUD 0.02 per ordinary share. The company targets an annual dividend payout ratio between 20% and 50% of net profit after tax.
Expansion and New Contracts
The company signed $41.3 million worth of contracts for the June '25 financial year, up 53% from the previous year. An additional $14.1 million worth of contracts were signed in the first few weeks of FY '26.
Partnership with Medidata
Cogstate's partnership with Medidata has led to seven studies being jointly awarded, a strong sales pipeline with 42 open opportunities, and increased reach into CNS indications.
AI Development and Market Expansion
Cogstate is set to launch its first AI-powered products in FY '26 to support further automation and scalability. The company is also expanding into psychiatric and mood disorders.
COGZF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
COGZF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 21, 2025 | $1.05 | $1.16 | +10.48% |
Feb 19, 2025 | $0.78 | $0.82 | +5.13% |
Aug 21, 2024 | $0.76 | $0.72 | -5.26% |
Feb 21, 2024 | $0.83 | $0.78 | -6.02% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Cogstate Ltd (COGZF) report earnings?
Cogstate Ltd (COGZF) is schdueled to report earning on Feb 25, 2026, Before Open (Confirmed).
What is Cogstate Ltd (COGZF) earnings time?
Cogstate Ltd (COGZF) earnings time is at Feb 25, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is COGZF EPS forecast?
Currently, no data Available